Concomitant blockade of both PD-1 and TIGIT intensifies the immunological response versus melanoma, so melanoma cells’ inhibition is much more effective than the use of anti-PD-1/PD-L1 alone in melanoma patients [203]. Here, PDCD1 is linked to melanoma.